CA
NZ
UK
AU
IND
US
Veeva Systems (NYSE:VEEV) reported a meaningful revenue increase for its fiscal third quarter ended October 31, 2025, supported by steady demand for its cloud-based solutions tailored to the life sciences sector. Totalrevenuerose 16%year-over-yearto USD 811.2 million, compared with USD 699.2 million in Q3 FY25. …
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) has initiated its Phase 3 CAREFNDR clinical trial evaluating paltusotine in adults with carcinoid syndrome, marking a major step toward expanding the therapeutic reach of its flagship drug. Carcinoid syndrome affects roughly 20 percent of people with neuroendocrine tumors, most …
SynCardia Systems, LLC, a subsidiary of Picard Medical Inc. (NASDAQ:PMI), has reached a defining moment in the advancement of artificial organ technology. The company confirmed the first successful in vivo implantations of its fully implantable Emperor Total Artificial Heart, marking a pivotal milestone in …
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the U.S.Food and Drug Administrationhas approved EYLEA HD (aflibercept injection 8 mg) for adult patients with macular edema following retinal vein occlusion. This approval adds a monthly (every four-week) dosing option across all previously approved indications, including wet …
Amgen (NASDAQ:AMGN) has received full approval from the U.S.Food and Drug Administrationfor IMDELLTRA (tarlatamab-dlle), a targeted therapy for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. This decision upgrades IMDELLTRA’s initial accelerated approval, marking a …
Gilead Sciences, Inc. (Nasdaq:GILD) has taken a crucial step in global HIV prevention with the first deliveries of its twice-yearly injectable PrEP medicine, lenacapavir, to Eswatini and Zambia. These shipments signify an important moment for communities in sub-Saharan Africa, a region that accounts for …
Zymeworks Inc. (Nasdaq:ZYME) has launched a strategic initiative designed to maximize long-term value from its growing roster of licensed biotherapeutics and healthcare assets. This decision follows encouraging developments across key programs, including positive topline data from the pivotal Phase 3 HERIZON-GEA-01 trial for Ziihera …
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) has achieved a major regulatory milestone as the U.S.Food and Drug Administration approvedREDEMPLO (plozasiran) for the treatment of adult patients with familial chylomicronemia syndrome. This marks the company’s first FDA-approved medicine and represents a pivotal step in its evolution from …
Genmab A/S (NASDAQ:GMAB) has received a major regulatory milestone with the U.S.Food and Drug Administrationgranting approval for EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide, collectively known as EPKINLY + R2, for adults with relapsed or refractory follicular lymphoma. This approval introduces the first-ever …
Olema Pharmaceuticals (NASDAQ:OLMA) gained significant market attention after Roche Holding AG (OTC:RHHBY) unveiled promising findings from its phase 3 lidERA trial evaluating giredestrant, an investigational oral selective estrogen receptor degrader, in patients with early-stage ER+/HER2- breast cancer. The large-scale study included more than 4,100 …
Please wait processing your request...